Trial Profile

Clinical study of ST-01156

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ST 01156 (Primary)
Indications Cancer
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

24 Apr 2025 According to SEED Therapeutics media release, SEED is rapidly transitioning into a clinical-stage company, with the planned IND filing for ST-01156 in the middle of this year.
31 Mar 2025 New trial record
27 Mar 2025 According to BeyondSpring Pharmaceuticals media release, RBM39 degrader expected to begin patient enrollment in second half of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com